Legal questions swirl around FDA’s new expedited drug program, including who should sign off

FDA staffers and outside experts worry the program runs afoul of legal, ethical and scientific standards used to review new ...

Takeaways from the AP's report on turmoil surrounding the FDA's new fast-track drug program

A plan to slash drug review times at the Food and Drug Administration is sparking deep concerns among agency staffers and ...